Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03886311 · ClinicalTrials.gov registry record · Phase 2
Talimogene Laherparepvec, Nivolumab and Trabectedin for Sarcoma
A Phase 2 study of Sarcoma, sponsored by Sarcoma Oncology Research Center.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 200
- Enrollment target
- 1
- Study location
NCT03886311: Recruiting Phase 2 study of Sarcoma, sponsored by Sarcoma Oncology Research Center.
NCT03886311 is a Phase 2 study of Sarcoma that is actively recruiting participants, run by Sarcoma Oncology Research Center. The registered enrollment target is 200 participants, below the 920-participant average among 122 other Sarcoma trials with a reported enrollment target (78% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03886311, a Phase 2 study of Sarcoma, is actively recruiting participants, sponsored by Sarcoma Oncology Research Center.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 200 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a Phase 2 study using talimogene laherparepvec, nivolumab, and trabectedin as first, second or third line therapy for advanced sarcoma, including desmoid tumor and chordoma.
Primary Outcome
Progression free survival at month 12
Conditions Studied
Interventions
- DRUG Talimogene Laherparepvec 100000000 PFU/1 ML Injection Suspension [IMLYGIC]
- DRUG Nivolumab IV Soln 100 MG/10ML
- DRUG Trabectedin 0.25 MG/1 VIAL Intravenous Powder for Solution
Study Locations (1)
California
- Sarcoma Oncology Center - Santa Monica
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2019-05-15 |
| Est. Completion | 2031-07-31 |
| Phase | Phase 2 |
What NCT03886311 shows while recruiting
NCT03886311 is an interventional study that assigns participants to a tested intervention. The registered 200 participants enrollment target is mid-sized for trials with a published cap, below the 920-participant average among 122 other Sarcoma trials with a reported enrollment target (78% lower).
The record links to 1 condition, with Sarcoma appearing as the primary indexed condition, and to 3 interventions - of which Talimogene Laherparepvec 100000000 PFU/1 ML Injection Suspension [IMLYGIC] is the first listed.
NCT03886311 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT03886311 about?
NCT03886311 is a clinical study titled "Talimogene Laherparepvec, Nivolumab and Trabectedin for Sarcoma". This is a Phase 2 study using talimogene laherparepvec, nivolumab, and trabectedin as first, second or third line therapy for advanced sarcoma, including desmoid tumor and chordoma.
What is the current status of trial NCT03886311?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 200 participants. The study started on 2019-05-15. Estimated completion is 2031-07-31.
What conditions does trial NCT03886311 study?
This clinical trial studies the following conditions: Sarcoma.
What interventions are being tested in trial NCT03886311?
The interventions under investigation include: Talimogene Laherparepvec 100000000 PFU/1 ML Injection Suspension [IMLYGIC] (DRUG), Nivolumab IV Soln 100 MG/10ML (DRUG), Trabectedin 0.25 MG/1 VIAL Intravenous Powder for Solution (DRUG).
Who is sponsoring clinical trial NCT03886311?
This trial is sponsored by Sarcoma Oncology Research Center, which has 8 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03886311 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Sarcoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03886311's enrollment target sits among peer trials
200 29th of 122 higher than 94 of 122 other Sarcoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Sarcoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of Cabozantinib as a Maintenance Agent to Prevent Progression or Recurrence in High-Risk Pediatric Solid Tumors
RECRUITING · Phase 2
-
A Study of AdAPT-001 in Subjects With Sarcoma and Refractory Solid Tumors
RECRUITING · Phase 2
-
Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial
RECRUITING · Phase 2
-
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
RECRUITING · Phase 2
-
Fluorescent Intra-operative Tumor Margin Examination
RECRUITING · Phase 2
-
Riluzole For Preventing Cognitive Dysfunction in Ca Pts Receiving Chemo (REFOCUS): Pilot Trial
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00107289 · 200 participants · Phase 2
Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma
- NCT00109174 · 200 participants · NA
MRS Measurement of Glutamate and GABA Metabolism in Brain
- NCT00177268 · 200 participants
Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research
- NCT00493688 · 200 participants
A Study to Determine Whether Perioperative Energy Dynamics Correlates With Postoperative Outcomes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI
- NCT06358040 · started 2026-10 · NA
Opioid Dispenser for Microdiscectomy/Laminectomy